These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 33193280)
21. Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Nelson JL; Rice KC; Slater SR; Fox PM; Archer GL; Bayles KW; Fey PD; Kreiswirth BN; Somerville GA Antimicrob Agents Chemother; 2007 Feb; 51(2):616-22. PubMed ID: 17130298 [TBL] [Abstract][Full Text] [Related]
22. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142 [TBL] [Abstract][Full Text] [Related]
23. Vancomycin MIC Distribution among Methicillin-Resistant Othman HB; Halim RMA; Gomaa FAM; Amer MZ Open Access Maced J Med Sci; 2019 Jan; 7(1):12-18. PubMed ID: 30740152 [TBL] [Abstract][Full Text] [Related]
24. Reconstruction of the Vancomycin-Susceptible Peng H; Rao Y; Yuan W; Zheng Y; Shang W; Hu Z; Yang Y; Tan L; Xiong K; Li S; Zhu J; Hu X; Hu Q; Rao X Front Microbiol; 2018; 9():2955. PubMed ID: 30546356 [TBL] [Abstract][Full Text] [Related]
25. Activated ADI pathway: the initiator of intermediate vancomycin resistance in Staphylococcus aureus. Tan XE; Neoh HM; Looi ML; Chin SF; Cui L; Hiramatsu K; Hussin S; Jamal R Can J Microbiol; 2017 Mar; 63(3):260-264. PubMed ID: 28059579 [TBL] [Abstract][Full Text] [Related]
26. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. Drummelsmith J; Winstall E; Bergeron MG; Poirier GG; Ouellette M J Proteome Res; 2007 Dec; 6(12):4690-702. PubMed ID: 17997515 [TBL] [Abstract][Full Text] [Related]
27. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Howden BP Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057 [TBL] [Abstract][Full Text] [Related]
28. Relationship between adhesin genes and biofilm formation in vancomycin-intermediate Staphylococcus aureus clinical isolates. Mirzaee M; Najar-Peerayeh S; Behmanesh M; Moghadam MF Curr Microbiol; 2015 May; 70(5):665-70. PubMed ID: 25572495 [TBL] [Abstract][Full Text] [Related]
29. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy. Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
31. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Cui L; Lian JQ; Neoh HM; Reyes E; Hiramatsu K Antimicrob Agents Chemother; 2005 Aug; 49(8):3404-13. PubMed ID: 16048954 [TBL] [Abstract][Full Text] [Related]
32. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus. Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329 [TBL] [Abstract][Full Text] [Related]
33. New Antimicrobial Resistance Strategies: An Adaptive Resistance Network Conferring Reduced Glycopeptide Susceptibility in VISA. Aguglia E; Chines E; Stefani S; Cafiso V Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107145 [No Abstract] [Full Text] [Related]
34. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus. Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792 [TBL] [Abstract][Full Text] [Related]
35. VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance. Gao C; Dai Y; Chang W; Fang C; Wang Z; Ma X Microbes Infect; 2019; 21(8-9):361-367. PubMed ID: 31009806 [TBL] [Abstract][Full Text] [Related]
36. Prevalence of vancomycin resistant Hasan R; Acharjee M; Noor R Ci Ji Yi Xue Za Zhi; 2016; 28(2):49-53. PubMed ID: 28757721 [TBL] [Abstract][Full Text] [Related]
38. Staphylococcus aureus infection induced redox signaling and DNA fragmentation in T-lymphocytes: possible ameliorative role of nanoconjugated vancomycin. Chakraborty SP; Das S; Chattopadhyay S; Tripathy S; Dash SK; Pramanik P; Roy S Toxicol Mech Methods; 2012 Apr; 22(3):193-204. PubMed ID: 22074192 [TBL] [Abstract][Full Text] [Related]